The Gammaretroviral p12 protein has multiple domains that function during the early stages of replication

Retrovirology

Volumn 9, Issue , 2012, Pages

  Wight, Darren J ^a   Boucherit, Virginie C ^a   Nader, Mirella ^a   Allen, David J ^a,b   Taylor, Ian A ^a   Bishop, Kate N ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Chromatin binding; MLV; p12; Post entry events; Retrovirus

Indexed keywords

MUTANT PROTEIN; PROTEIN P12; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHIMERA; CHROMATIN; CONTROLLED STUDY; GENE MUTATION; GIBBON LEUKEMIA VIRUS; HUMAN; HUMAN CELL; MOLONEY LEUKEMIA ONCOVIRUS; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEFECT; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN MOTIF; RETROVIRUS; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS CORE; VIRUS INFECTIVITY; VIRUS LIKE AGENT; VIRUS MUTANT; VIRUS REPLICATION; WILD TYPE;

DNA MUTATIONAL ANALYSIS; GENE PRODUCTS, GAG; LEUKEMIA VIRUS, GIBBON APE; MOLONEY MURINE LEUKEMIA VIRUS; MUTANT PROTEINS; VIRUS REPLICATION;

HYLOBATIDAE; MIRIDAE; MURINAE;

EID: 84866897217     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-9-83     Document Type: Article

References (37)

1. Goff SP. Host factors exploited by retroviruses. Nat Rev Microbiol 2007, 5:253-263. 10.1038/nrmicro1541, 17325726.
2. Wolf D, Goff SP. Host restriction factors blocking retroviral replication. Annu Rev Genet 2008, 42:143-163. 10.1146/annurev.genet.42.110807.091704, 18624631.
3. Freed EO. Viral late domains. J Virol 2002, 76:4679-4687. 10.1128/JVI.76.10.4679-4687.2002, 136167, 11967285.
4. Martin-Serrano J, Zang T, Bieniasz PD. Role of ESCRT-I in retroviral budding. J Virol 2003, 77:4794-4804. 10.1128/JVI.77.8.4794-4804.2003, 152150, 12663786.
5. Gottlinger HG, Dorfman T, Sodroski JG, Haseltine WA. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A 1991, 88:3195-3199. 10.1073/pnas.88.8.3195, 51412, 2014240.
6. Huang M, Orenstein JM, Martin MA, Freed EO. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol 1995, 69:6810-6818. 189593, 7474093.
7. Crawford S, Goff SP. Mutations in gag proteins P12 and P15 of Moloney murine leukemia virus block early stages of infection. J Virol 1984, 49:909-917. 255553, 6608006.
8. Yuan B, Li X, Goff SP. Mutations altering the moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle. EMBO J 1999, 18:4700-4710. 10.1093/emboj/18.17.4700, 1171543, 10469649.
9. Auerbach MR, Shu C, Kaplan A, Singh IR. Functional characterization of a portion of the Moloney murine leukemia virus gag gene by genetic footprinting. Proc Natl Acad Sci U S A 2003, 100:11678-11683. 10.1073/pnas.2034020100, 208817, 14504385.
10. Yuan B, Fassati A, Yueh A, Goff SP. Characterization of Moloney Murine Leukemia Virus p12 Mutants Blocked during Early Events of Infection. J Virol 2002, 76:10801-10810. 10.1128/JVI.76.21.10801-10810.2002, 136648, 12368323.
11. Ciuffi A, Bushman FD. Retroviral DNA integration: HIV and the role of LEDGF/p75. Trends Genet 2006, 22:388-395. 10.1016/j.tig.2006.05.006, 16730094.
12. Maertens G, Cherepanov P, Pluymers W, Busschots K, De Clercq E, Debyser Z, Engelborghs Y. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem 2003, 278:33528-33539. 10.1074/jbc.M303594200, 12796494.
13. Yueh A, Goff SP. Phosphorylated Serine Residues and an Arginine-Rich Domain of the Moloney Murine Leukemia Virus p12 Protein Are Required for Early Events of Viral Infection. J Virol 2003, 77:1820-1829. 10.1128/JVI.77.3.1820-1829.2003, 140972, 12525616.
14. Ikuta K, Luftig RB. Detection of phosphorylated forms of Moloney murine leukemia virus major capsid protein p30 by immunoprecipitation and two-dimensional gel electrophoresis. J Virol 1988, 62:40-46. 250499, 3334749.
15. Dodding MP, Bock M, Yap MW, Stoye JP. Capsid processing requirements for abrogation of Fv1 and Ref1 restriction. J Virol 2005, 79:10571-10577. 10.1128/JVI.79.16.10571-10577.2005, 1182663, 16051849.
16. Oshima M, Muriaux D, Mirro J, Nagashima K, Dryden K, Yeager M, Rein A. Effects of Blocking Individual Maturation Cleavages in Murine Leukemia Virus Gag. J Virol 2004, 78:1411-1420. 10.1128/JVI.78.3.1411-1420.2004, 321369, 14722296.
17. Kyere SK, Joseph PRB, Summers MF. The p12 domain is unstructured in a murine leukemia virus p12-CA(N) Gag construct. PLoS One 2008, 3:e1902. 10.1371/journal.pone.0001902, 2277328, 18382677.
18. Nandhagopal N, Simpson AA, Johnson MC, Francisco AB, Schatz GW, Rossmann MG, Vogt VM. Dimeric rous sarcoma virus capsid protein structure relevant to immature Gag assembly. J Mol Biol 2004, 335:275-282. 10.1016/j.jmb.2003.10.034, 14659756.
19. Lee S, Nagashima K. Cooperative effect of gag proteins p12 and capsid during early events of murine leukemia virus replication. J Virol 2005, 79:4159-4169. 10.1128/JVI.79.7.4159-4169.2005, 1061564, 15767417.
20. Prizan-Ravid A, Elis E, Laham-Karam N, Selig S, Ehrlich M, Bacharach E. The Gag cleavage product, p12, is a functional constituent of the murine leukemia virus pre-integration complex. PLoS Pathog 2010, 6:e1001183. 10.1371/journal.ppat.1001183, 2978732, 21085616.
21. Zhang F, Zang T, Wilson SJ, Johnson MC, Bieniasz PD. Clathrin facilitates the morphogenesis of retrovirus particles. PLoS Pathog 2011, 7:e1002119. 10.1371/journal.ppat.1002119, 3128127, 21738476.
22. Popov S, Strack B, Sanchez-Merino V, Popova E, Rosin H, Gottlinger HG. Human immunodeficiency virus type 1 and related primate lentiviruses engage clathrin through Gag-Pol or Gag. J Virol 2011, 85:3792-3801. 10.1128/JVI.02329-10, 3126147, 21289110.
23. Stevens A, Bock M, Ellis S, LeTissier P, Bishop KN, Yap MW, Taylor W, Stoye JP. Retroviral capsid determinants of Fv1 NB and NR tropism. J Virol 2004, 78:9592-9598. 10.1128/JVI.78.18.9592-9598.2004, 514981, 15331691.
24. Mullers E, Stirnnagel K, Kaulfuss S, Lindemann D. Prototype foamy virus gag nuclear localization: a novel pathway among retroviruses. J Virol 2011, 85:9276-9285. 10.1128/JVI.00663-11, 3165767, 21715475.
25. Tobaly-Tapiero J, Bittoun P, Lehmann-Che J, Delelis O, Giron ML, de The H, Saib A. Chromatin tethering of incoming foamy virus by the structural Gag protein. Traffic 2008, 9:1717-1727. 10.1111/j.1600-0854.2008.00792.x, 18627573.
26. De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007, 6:1001-1018. 10.1038/nrd2424, 18049474.
27. Henderson LE, Gilden RV, Oroszlan S. Amino acid sequence homology between histone H5 and murine leukemia virus phosphoprotein p12. Science 1979, 203:1346-1348. 10.1126/science.218289, 218289.
28. Ohkura S, Goldstone DC, Yap MW, Holden-Dye K, Taylor IA, Stoye JP. Novel escape mutants suggest an extensive TRIM5alpha binding site spanning the entire outer surface of the murine leukemia virus capsid protein. PLoS Pathog 2011, 7:e1002011. 10.1371/journal.ppat.1002011, 3068999, 21483490.
29. Hulme AE, Perez O, Hope TJ. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc Natl Acad Sci U S A 2011, 108:9975-9980. 10.1073/pnas.1014522108, 3116424, 21628558.
30. Perez-Caballero D, Hatziioannou T, Zhang F, Cowan S, Bieniasz PD. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol 2005, 79:15567-15572. 10.1128/JVI.79.24.15567-15572.2005, 1316013, 16306627.
31. Bock M, Bishop KN, Towers G, Stoye JP. Use of a transient assay for studying the genetic determinants of Fv1 restriction. J Virol 2000, 74:7422-7430. 10.1128/JVI.74.16.7422-7430.2000, 112262, 10906195.
32. Mothes W, Boerger AL, Narayan S, Cunningham JM, Young JA. Retroviral entry mediated by receptor priming and low pH triggering of an envelope glycoprotein. Cell 2000, 103:679-689. 10.1016/S0092-8674(00)00170-7, 11106737.
33. Yap MW, Nisole S, Lynch C, Stoye JP. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci U S A 2004, 101:10786-10791. 10.1073/pnas.0402876101, 490012, 15249690.
34. Groom HC, Boucherit VC, Makinson K, Randal E, Baptista S, Hagan S, Gow JW, Mattes FM, Breuer J, Kerr JR, et al. Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 2010, 7:10. 10.1186/1742-4690-7-10, 2839973, 20156349.
35. Groom HC, Yap MW, Galao RP, Neil SJ, Bishop KN. Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc Natl Acad Sci U S A 2010, 107:5166-5171. 10.1073/pnas.0913650107, 2841911, 20194752.
36. Bruce JW, Bradley KA, Ahlquist P, Young JA. Isolation of cell lines that show novel, murine leukemia virus-specific blocks to early steps of retroviral replication. J Virol 2005, 79:12969-12978. 10.1128/JVI.79.20.12969-12978.2005, 1235846, 16188999.
37. Vistica J, Dam J, Balbo A, Yikilmaz E, Mariuzza RA, Rouault TA, Schuck P. Sedimentation equilibrium analysis of protein interactions with global implicit mass conservation constraints and systematic noise decomposition. Anal Biochem 2004, 326:234-256. 10.1016/j.ab.2003.12.014, 15003564.